Wang Xue-Yan, Chen Hong-Song
Xue-Yan Wang, Hong-Song Chen, Peking University Hepatology Institute, Peking University People's Hospital, Beijing 100044, China.
World J Gastroenterol. 2014 Jun 28;20(24):7707-17. doi: 10.3748/wjg.v20.i24.7707.
Chronic infection with hepatitis B virus (HBV) constitutes a major global public health threat, causing substantial disease burdens such as liver cirrhosis and hepatocellular carcinoma, thus representing high unmet medical needs. Currently available therapies are safe, well tolerated, and highly effective in decreasing viremia and improving measured clinical outcomes with low rates of antiviral resistance. However, long-term management remains a clinical challenge, mainly due to the slow kinetics of HBV surface antigen clearance. In this article, we review emerging antivirals directed at novel targets derived from mechanisms of viral cellular entry, viral replication, viral assembly, and the host immune response, leading to preclinical and clinical trials for possible future therapeutic intervention. The recent therapeutic advances in the development of all categories of HBV inhibitors may pave the way for regimens of finite duration that result in long-lasting control of chronic hepatitis B infection.
慢性乙型肝炎病毒（HBV）感染是全球主要的公共卫生威胁，会导致肝硬化和肝细胞癌等严重疾病负担，因此存在大量未满足的医疗需求。目前可用的疗法安全、耐受性良好，在降低病毒血症和改善可测量的临床结果方面非常有效，且抗病毒耐药率较低。然而，长期管理仍然是一项临床挑战，主要原因是HBV表面抗原清除动力学缓慢。在本文中，我们综述了针对病毒细胞进入、病毒复制、病毒组装和宿主免疫反应机制的新型靶点的新兴抗病毒药物，这些药物已进入临床前和临床试验阶段，有望在未来进行治疗干预。各类HBV抑制剂开发方面的最新治疗进展可能为实现有限疗程并长期控制慢性乙型肝炎感染的治疗方案铺平道路。
